Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LCAR-C182A

Cell therapy (CAR-T) · Kills target cells, directed at Claudin 18.2 (CLDN18)

Early Phase 1 Most advanced trial (none active)
1 Registered trials

What is LCAR-C182A?

LCAR-C182A is a CAR-T cell therapy given after lymphodepleting fludarabine and cyclophosphamide. It is studied in gastric cancer and pancreatic ductal adenocarcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Cell therapy (CAR-T)
Targets
Claudin 18.2 (CLDN18) (antigen)
Mechanism
Kills target cells, directed at Claudin 18.2 (CLDN18)
Therapy area
Oncology
In trials of
LEGN
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03890198 Early Phase 1 Gastric Cancer Terminated LEGN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Gastric CancerPancreatic Ductal Adenocarcinoma

Other drugs acting on CLDN18

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.